This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.rt.com/news/517808-denmark-minister-astrazeneca-covid19-vaccine/

The article has changed 3 times. There is an RSS feed of changes available.

Version 0 Version 1
Denmark, Estonia, Lithuania, Luxembourg, Latvia suspend AstraZeneca Covid vaccine after reports of potentially fatal blood clots Denmark, Estonia, Lithuania, Luxembourg, Latvia suspend AstraZeneca Covid vaccine after reports of potentially fatal blood clots
(6 months later)
The rollout of the AstraZeneca Covid vaccine in Denmark, Estonia, Lithuania, Luxembourg, Latvia has been suspended as the health authorities investigate a possibly serious side effect in the form of fatal blood clots.The rollout of the AstraZeneca Covid vaccine in Denmark, Estonia, Lithuania, Luxembourg, Latvia has been suspended as the health authorities investigate a possibly serious side effect in the form of fatal blood clots.
On Thursday, Danish Health Minister Magnus Heunicke tweeted that the country would be suspending the use of the Anglo-Swedish vaccine, which has already come under intense scrutiny across Europe and further afield. On Thursday, Danish Health Minister Magnus Heunicke tweeted that the country would be suspending the use of the Anglo-Swedish vaccine, which has already come under intense scrutiny across Europe and further afield. 
“The health authorities have, due to precautionary measures, suspended vaccination with AstraZeneca following a signal of a possible serious side effect in the form of fatal blood clots. It is currently not possible to conclude whether there is a connection. We act early, it needs to be thoroughly investigated #COVID19dk,” Heunicke wrote on Twitter.“The health authorities have, due to precautionary measures, suspended vaccination with AstraZeneca following a signal of a possible serious side effect in the form of fatal blood clots. It is currently not possible to conclude whether there is a connection. We act early, it needs to be thoroughly investigated #COVID19dk,” Heunicke wrote on Twitter.
This news comes after the European Medicines Agency (EMA) on Wednesday published its view on a number of side effects supposedly linked to the administration of the AstraZeneca vaccine in Austria. This news comes after the European Medicines Agency (EMA) on Wednesday published its view on a number of side effects supposedly linked to the administration of the AstraZeneca vaccine in Austria. 
Austrian authorities suspended the use of a batch of AstraZeneca Covid-19 jabs after a person was diagnosed with multiple thrombosis (formation of blood clots within blood vessels) and died 10 days after vaccination. Another was hospitalized with a pulmonary embolism and there were two further reports of thromboembolic event incidents linked to the batch.Austrian authorities suspended the use of a batch of AstraZeneca Covid-19 jabs after a person was diagnosed with multiple thrombosis (formation of blood clots within blood vessels) and died 10 days after vaccination. Another was hospitalized with a pulmonary embolism and there were two further reports of thromboembolic event incidents linked to the batch.
The EMA said there is “no indication that vaccination has caused these conditions.”The EMA said there is “no indication that vaccination has caused these conditions.”
Estonia, Lithuania, Luxembourg, Latvia also suspended the use of the batch following the news from Austria.Estonia, Lithuania, Luxembourg, Latvia also suspended the use of the batch following the news from Austria.
AstraZeneca’s vaccine has been widely administered around the world, including the UK where more than 24 million jabs have been given, the majority of which were developed by the Anglo-Swedish pharmaceutical firm.AstraZeneca’s vaccine has been widely administered around the world, including the UK where more than 24 million jabs have been given, the majority of which were developed by the Anglo-Swedish pharmaceutical firm.
If you like this story, share it with a friend!If you like this story, share it with a friend!
Dear readers and commenters,
We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.
Sorry for the inconvenience, and looking forward to your future comments,
RT Team.